July 2024

TAIPEI, July 11, 2024 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), announced IND Submission to US FDA for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors. This investigator-initiated tr

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: